Clinical and Imaging Features Preoperative Evaluation of Histological Grade and Microvascular Infiltration of Hepatocellular Carcinoma
Overview
Affiliations
Background: To predict the histological grade and microvascular invasion (MVI) in patients with HCC.
Methods: A retrospective analysis was conducted on 175 patients who underwent MRI enhancement scanning (from September 2016.9 to October 2020). They were divided into MVI positive, MVI negative, Grade-high and Grade-low groups.
Results: The AFP of 175 HCC patients distributed in MVI positive and negative groups, Grade-low and Grade-high groups were statistically significant (P = 0.002 and 0.03, respectively). Multiple HCC lesions were more common in MVI positive and Grade-high groups. Correspondingly, more single lesions were found in MVI negative and Grade-low groups (P = 0.005 and 0.019, respectively). Capsule on MRI was more common in MVI negative and Grade-high groups, and the difference was statistically significant (P = 0.02 and 0.011, respectively). There were statistical differences in the distribution of three MRI signs: artistic rim enhancement, artistic peripheral enhancement, and tumor margin between MVI positive and MVI negative groups (P = 0.001, < 0.001, and < 0.001, respectively). Tumor hypointensity on HBP was significantly different between MVI positive and negative groups (P < 0.001).
Conclusions: Our research shows that preoperative enhanced imaging can be used to predict MVI and tumor differentiation grade of HCC. The prognosis of MVI-negative group was better than that of MVI-positive group.
Ghenciu L, Grigoras M, Rosu L, Bolintineanu S, Sima L, Cretu O Biomedicines. 2025; 13(1.
PMID: 39857748 PMC: 11759174. DOI: 10.3390/biomedicines13010164.
Zhang W, Guo Q, Zhu Y, Wang M, Zhang T, Cheng G Cancer Imaging. 2024; 24(1):142.
PMID: 39438929 PMC: 11520182. DOI: 10.1186/s40644-024-00790-9.
Chen Z, Li X, Zhang Y, Yang Y, Zhang Y, Zhou D J Hepatocell Carcinoma. 2023; 10:1595-1608.
PMID: 37786565 PMC: 10541533. DOI: 10.2147/JHC.S422632.
Imaging prognostication and tumor biology in hepatocellular carcinoma.
Kadi D, Yamamoto M, Lerner E, Jiang H, Fowler K, Bashir M J Liver Cancer. 2023; 23(2):284-299.
PMID: 37710379 PMC: 10565542. DOI: 10.17998/jlc.2023.08.29.
Gu Y, Huang H, Tong Q, Cao M, Ming W, Zhang R Cancers (Basel). 2023; 15(8).
PMID: 37190266 PMC: 10137067. DOI: 10.3390/cancers15082338.